Noa Lavi

Technion – Israel Institute of Technology — Israel

Medicine · Health Sciences

21h-index1.3kcitations105works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(52), Myeloproliferative Neoplasms: Diagnosis and Treatment(23), Protein Degradation and Inhibitors(18), Acute Myeloid Leukemia Research(14), Peptidase Inhibition and Analysis(11)

Publications105 total

Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study
Blood·2025Open Access
First-in-Human, Open-Label, Phase 1 Trial Design of SAR446523, a Novel Anti-GPRC5D Antibody-Dependent Cellular Cytotoxicity (ADCC)-Enhanced Monoclonal Antibody for Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Blood Advances·2025· 2 citedOpen Access
Identification of needs of patients with multiple myeloma: a questionnaire-based study in Israeli patients
Acta Haematologica·2025Open Access
Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
Blood·2024
<i>Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial</i>
Blood·2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature
Acta Haematologica·2024· 5 citedOpen Access
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study
Acta Haematologica·2024· 2 cited
Research note: Autonomous hunter-gatherer children in hierarchical schools: a review of the literature from the global South
Hunter Gatherer Research·2024· 2 citedOpen Access
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)
Blood·2023Open Access
Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience
Blood·2023· 2 cited
MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
HemaSphere·2023· 1 citedOpen Access
P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
HemaSphere·2023· 1 citedOpen Access
P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
HemaSphere·2023Open Access
P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
HemaSphere·2023· 3 citedOpen Access
Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2023
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Journal of Clinical Oncology·2023· 17 cited
Data from Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Irit Avivi(21), Yaël C. Cohen(15), Moshe E. Gatt(15), Chezi Ganzel(11), Tamar Tadmor(11), Netanel A. Horowitz(11), Tsila Zuckerman(9), Hila Magen(9), Ilana Oren(8), Evgeni Chubar(7), Martin Ellis(7), Celia Suriu(7), Iuliana Vaxman(6), Noam Benyamini(6), Maya Koren‐Michowitz(6), Svetlana Trestman(6), Ory Rouvio(5), Yishai Ofran(5), Jacob M. Rowe(5), Miri Zektser(5)